Fig. 1: Antitumor responses achieved by CD47KO tumor cell vaccination.
From: Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice
a Representative flow cytometry profiles showing CD47 expression on wild-type (WT) and CD47KO B16F0 cells. CD47KO cells were generated by CRISPR/Cas9-targeted inactivation of cd47 gene. b B6 mice were injected (i.s.) with media (n = 19), or with irradiated WT (n = 16) or CD47KO (n = 20) B16F0 cells, followed 7 days later by subcutaneous injection of 2 × 105 WT B16F0 melanoma cells. c B6 mice were injected (i.s.) with media (n = 4 at days 11 and 13; n = 9 at other time points), or with WT (n = 4 at days 11 and 13; n = 7 at all other time points) or CD47KO (n = 5 at days 11 and 13; n = 10 at all other time points) B16F0 cells that were treated with mitomycin C (at 40 µg/mL for 2h), followed 7 days later by subcutaneous injection of 2 × 105 WT B16F0 melanoma cells. d Spleen cells were harvested from mice 7 days after vaccination with irradiated WT or CD47KO B16F0 cells or media, and IFN-γ production was measured by ELISPOT assay (n = 3 per group). Results are presented as mean ± SD (*p < 0.05, **p < 0.01; unpaired t-test). e B6 mice were pre-inoculated subcutaneously with 1 × 105 WT B16F0 melanoma cells, followed 1 day later by vaccination (i.s.) with media (n = 6) or irradiated CD47KO B16F0 cells (n = 5). f Tumor-free mice in the group vaccinated with irradiated CD47KO B16F0 cells 30 days after first tumor cell injection were re-challenged with 2 × 105 B16F0 cells (n = 7). Age-matched naïve mice were used as the controls (n = 3). Each symbol represented an individual mouse. Source data are provided as a Source Data file.
